The pan-Canadian Pharmaceutical Alliance (pCPA) negotiation process for Welireg (belzutifan) concluded on 2024-08-30.
Indication(s): Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Negotiation Status: Concluded with an LOI
Official pCPA posting here: https://www.pcpacanada.ca/negotiation/22455
We now urge the provinces for timely implementation!